Your Article Summary
See Latest ArticlesYttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkins lymphoma
Investigational New Drugs, 06/26/09
Kang BW et al. - 90Y-ibritumomab with Bu/Cy/E and ASCT is feasible in patients with relapsed or refractory B-cell NHL, without increased toxicity.
Related Articles
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: Eighty-month follow-up
Bone Marrow Transplantation, 11/13/09
Relevance Score: 83%%
Stem cell therapy for age-related retinal disease
Aging Health, 11/23/09
Relevance Score: 82%%
Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia
Transplantation Proceedings, 11/23/09
Relevance Score: 82%%
Successful Immunotherapy of HCMV Disease Using Virus-Specific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient
American Journal of Transplantation, 11/18/09
Relevance Score: 82%%
Regulatory T Cell (Treg) Subsets Return in Patients with Refractory Lupus following Stem Cell Transplantation, and TGF-[beta]-Producing CD8+ Treg Cells Are Associated with Immunological Remission of Lupus
Journal of Immunology, 11/10/09
Relevance Score: 82%%
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
Mobilization of hematopoietic stem cells into the peripheral blood
Expert Review of Hematology, 12/02/09
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma
International Journal of Hematology, 12/01/09
KIR and HLA Genotypes Are Associated with Disease Progression and Survival following Autologous Hematopoietic Stem Cell Transplantation for High-Risk Neuroblastoma
Clinical Cancer Research, 12/01/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole
Breast Cancer Research and Treatment, 12/02/09
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Breast Cancer Research and Treatment, 12/02/09
FDA Drug Approval Summary: Bevacizumab (Avastin) as Treatment of Recurrent Glioblastoma Multiforme
The Oncologist, 12/02/09